{
  "id": 1717708,
  "title": "STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more",
  "url": "https://urgent.news/2026/08/18/stat-pharmalittle-were-reading-about-a-setback-for-eyepoint-a-win-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T13:25:37.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/08/18/eyepoint-blindness-treatment-setback-amylyx-avexitide-win/"
  },
  "original_language": "en",
  "account": "Eyepoint reported that its experimental treatment for age-related blindness did not meet its primary goal in a Phase 3 clinical trial, according to STAT. This setback threatened the drug's regulatory approval process and led to a decline in its stock price. Ocular Therapeutix, which intends to seek approval for a competing treatment later this year, saw its shares rise due to the news. Both companies work on drugs to preserve vision in individuals with wet age-related macular degeneration.\n\nNovartis decided not to pursue reimbursement for Vanrafia, its newly approved treatment for a rare kidney disease, in Canada. The decision was based on the current \"access environment,\" reported CityNews Toronto. Health Canada approval is just the beginning of a lengthy process required for drug companies before their products reach pharmacies and medicine cabinets. According to data from the Canada Drug Agency, fewer than 50% of medicines approved by Health Canada make it to the next stage, limiting their availability through hospitals and private and public insurance.",
  "summary": "Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more",
        "url": "https://urgent.news/2026/08/17/stat-pharmalittle-were-reading-about-an-astrazeneca-setback-falling-u",
        "published": "2026-08-17T13:22:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}